Merck entered a discovery collaboration with Infinimmune to develop multiple therapeutic antibodies across immune-related targets. The agreement provides for up to $838 million in upfront and milestone payments, with Merck holding exclusive development and commercialization rights for candidates produced through the platform. Infinimmune’s approach leverages AI-driven analysis of human immune-cell libraries to identify potential targets for conditions including IL-22 and IL-13-linked autoimmune diseases.